Literature DB >> 11478901

Time-dependent inhibition of protein farnesyltransferase by a benzodiazepine peptide mimetic.

R Roskoski1, P A Ritchie.   

Abstract

Protein farnesyltransferase (FTase) and protein geranylgeranyltransferase-I (GGTase-I) catalyze the prenylation of proteins with a carboxy-terminal tetrapeptide sequence called a CaaX box, where C refers to cysteine, "a" refers to an aliphatic residue, and X typically refers to methionine, serine, or glutamine (FTase), or to leucine (GGTase-I). Marsters and co-workers [(1994) Bioorg. Med. Chem. 2, 949--957] developed inhibitors of FTase with cysteine and methionine attached to an inner hydrophobic benzodiazepine scaffold. We found that the most potent of these compounds (BZA-2B) resulted in the time-dependent inhibition of FTase. The K(i) of BZA-2B for FTase, which is the dissociation constant of the initial complex, was 79 +/- 13 nM, and the K(i)*, which is the overall dissociation of inhibitor for all enzyme forms, was 0.91 +/- 0.12 nM. The first-order rate constant for the conversion of the initial complex to the final complex was 1.4 +/- 0.2 min(-1), and that for the reverse process was 0.016 +/- 0.002 min(-1). The latter rate constant corresponds to a half-life of the final complex of 45 min. Our experiments favor the notion that the inhibitor binds to the FTase--farnesyl diphosphate complex which then undergoes an isomerization to form a tighter FTase*--farnesyl diphosphate--BZA2-B complex. Diazepam, a compound with a benzodiazepine nucleus but lacking amino acid extensions, was a weak (K(i) = 870 microM) but not time-dependent inhibitor of FTase. Cys-Val-Phe-Met and Cys-4-aminobenzoyl-Met were instantaneous and not time-dependent inhibitors of FTase. Furthermore, BZA-4B, with a leucine specificity determinant, was a classical competitive inhibitor of GGTase-I and not a time-dependent inhibitor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11478901     DOI: 10.1021/bi010290b

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  2 in total

1.  Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.

Authors:  Amanda J DeGraw; Michael J Keiser; Joshua D Ochocki; Brian K Shoichet; Mark D Distefano
Journal:  J Med Chem       Date:  2010-03-25       Impact factor: 7.446

2.  Antidepressant/anxiolytic and anti-nociceptive effects of novel 2-substituted 1,4-benzodiazepine-2-ones.

Authors:  Harjit Singh; Jintana Sattayasai; Pornthip Lattmann; Yodchai Boonprakob; Eric Lattmann
Journal:  Sci Pharm       Date:  2010-05-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.